Atrial fibrillation, thromboembolism and antithrombotic therapy

International Journal of Clinical Practice

Volumn 53, Issue 2, 1999, Pages 110-117

  Li Saw Hee, F L ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; HEPARIN; INDOBUFEN; WARFARIN;

BLEEDING; CLINICAL TRIAL; HEART ATRIUM FIBRILLATION; HEART RHYTHM; HUMAN; MAJOR CLINICAL STUDY; MONITORING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; HUMANS; MIDDLE AGED; THROMBOEMBOLISM; WARFARIN;

EID: 0033058752     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ 1964; 1: 1209-1212.
2. Fleming HA, Bailey SM. Mitral valve disease, systemic embolism and anticoagulants. Postgrad Med J 1995; 47: 599-604.
3. Feinberg WM, Blackshear JL, Laupacis A et al. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155: 469-473.
4. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952.
5. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
6. Hofmann T, Kasper W, Meinertz T et al. Echocardiographic evaluation of patients with clinically suspected arterial thrombi. Lancet 1990; 336: 1421-1424.
7. Nishide M, Irino T, Gotoh M et al. Cardiac abnormalities in ischaemic cerebrovascular disease studied by two-dimensional echocardiography. Stroke 1983; 14: 541-545.
8. Sherman DG, Dyken ML, Fisher M et al. Antithrombotic therapy for cerebrovascular disorders. Chest 1990; 95(suppl): 140S-155S.
9. Cohen BA, Hilderbrand F, Biller J. Cardioembolic stroke, Part 1: Clinical patterns and associated cardiac conditions. ACC Curr Rev J 1993; 2: 51-52.
10. Beppu S, Park YD, Sakakibara H et al. Clinical features of intracardiac thrombosis based on echocardiographic observation. Jpn Circ J 1984: 48: 75-82.
11. Black IW, Hopkins AP, Lee LC et al. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol 1991; 18: 398-404.
12. Tsai LM, Chen JH, Fang CJ et al. Clinical implications of left atrial spontaneous echo contrast in nonrheumatic atrial fibrillation. Am J Cardiol 1992; 70: 327-331.
13. Chiang CW, Lo SK, Ko YS et al. Predictors of systemic embolism in patients with mitral stenosis. Ann Intern Med 1998; 128: 885-889.
14. Kapila A, Hart R. Calcific cerebral emboli and aortic stenosis: detection of computed tomography. Stroke 1986; 17: 619-621.
15. Rancurel G, Marelle L, Vincent C et al. Spontaneous calcific cerebral embolus from a cardiac aortic stenosis in a middle cerebral artery infarct. Stroke 1989; 20: 691-693.
16. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 1991; 22: 983.
17. Lip GYH, Golding D, Nazir M et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997: 47: 285-289.
18. Zarifis J Beevers DG, Lip GYH. Acute admissions with atrial fibrillation in a British multiracial hospital population. Br J Clin Pract 1997; 51(2): 91-96.
19. Lip GYH, Bawden L, Hodson R et al. Atrial fibrillation amongst the Indo-Asian general practice population: the West Birmingham Atrial Fibrillation Project. Int J Cardiol 1998; 65: 187-192.
20. American Heart Association. Heart and stroke facts statistical update. Office of Scientific Affairs, American Heart Association. Dallas, Texas, 1997.
21. Sherman DG, Dyken ML Jr, Gent M et al. Antithrombotic therapy for cerebrovascular disorders: an update. Chest 1995; 108: 444s-456s.
22. Lowe GD, Jaap AJ, Forbes CD. Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet 1983; i: 784-786.
23. Sandercock P, Bamford J, Dennis M et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis. BMJ 1992; 305: 1460-1465.
24. Jorgensen HS, Nakayama H, Reith J et al. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997; 48: 891-895.
25. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764.
26. The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from three randomized trials. Arch Intern Med 1997; 157: 1237-1240.
27. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
28. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527-539.
29. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
30. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; i: 175-179.
31. Sudlow CM, Rodgers H, Kenny RA, Thomson RG. Service provision and use of anticoagulants in atrial fibrillation. BMJ 1995; 311: 558-561.
32. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994; 154: 1945-1953.
33. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
34. Gustafsson C, Asplund K, Britton M et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457-1460.
35. Lancaster TR, Singer DE, Sheehan MA et al. The impact of long-term warfarin therapy on quality of life: evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med 1991; 1: 1944-1949.
36. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med 1996; 335: 540-546.
37. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409-416.
38. Coon WW, Willis PW III. Hemorrhagic complications of anticoagulant therapy. Arch Intern Med 1974; 133: 386-392.
39. Wintzen AR, de Jonge H, Loeliger EA, Bots GT. The risk of intracerebral hemorrhage during oral anticoagulation treatment: a population study. Ann Neurol 1984; 16: 553-558.
40. Forfar JC. A 7-year analysis of haemorrhage in patients on long term anticoagulant treatment. Br Heart J 1979; 42: 128-132.
41. Gurwitz JH, Goldberg RJ, Holden A et al. Age-related risks of long term oral anticoagulant therapy. Arch Intern Med 1988; 148: 1733-1736.
42. Enrichete AM, Holden A, Ansell J. Management of oral anticoagulant therapy: experience with an anticoagulant clinic. Arch Intern Med 1985; 144: 1966-1968.
43. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: Stroke Prevention In Atrial Fibrillation III randomized clinical trial. Lancet 1996; 348: 633-638.
44. Pengo V, Zasso A, Barbero F et al. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in non-rheumatic atrial fibrillation. Am J Cardiol 1998; 82: 433-437.
45. Gullov AL, Koefoed BG, Petersen P et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: second Copenhagen AFASAK Study. Arch Intern Med 1998; 158: 1513-1521.
46. Hellemons BSP, Langenberg M, Lodder J et al. Primary prevention of arterial thromboembolism in patients with nonrheumatic atrial fibrillation in general practice (the PATAF study). Cerebrovas Dis 1997; 7(suppl 4): 11 (abstract).
47. Sudlow M, Thomson R, Thwaites B et al. Prevalence of atrial fibrillation and eligilibily for anticoagulants in the community. Lancet 1998; 352: 1167-1171.
48. McCrory DC, Matchar DB, Smasa G et al. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: 277-281.
49. Kutner M, Nixon G, Silverstone F. Physicians' attitudes towards oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151: 1950-1953.
50. Thomson R, McElroy H, Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ 1998; 316: 509-513.
51. Lip GYH, Zarifis J, Watson RD, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart 1996: 7: 200-205.
52. Pell JP, McIver B, Stuart P et al. Comparison of anticoagulant control among patients attending general practice and a hospital anticoagulant clinic. Br J Gen Pract 1993; 43: 152-154.
53. Taylor F, Ramsay M, Voke J, Cohen H. Anticoagulation in patients with atrial fibrillation: GPs not prepared for monitoring anticoagulation. BMJ 1993; 307: 1493.
54. Rogers H, Sudlow M, Dobson R et al. Warfarin anticoagulation in primary care: a regional survey of present practice and clinicians' views. Br J Gen Pract 1997; 47: 309-310.
55. Fitzmaurice DA, Hobbs FD, Murray ET. Primary care anticoagulant clinic management using computerized decision support and near patient International Normalized Ratio (INR) testing: routine data from a practice nurse-led clinic. Fam Pract 1998; 15: 144-146.
56. Kistler JP, Singer DE, Millenson MM et al. Effect of low-intensily warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. Stroke 1993; 24: 1360-1365.
57. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplalelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
58. Morocutti C, Amabile G, Fattapposta F et al, for the SIFA (Studio Italiano Fibrillazione Atrial) investigators. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997; 28: 1015-1021.
59. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neural Sci 1996; 143: 1-13.
60. Forbes CD. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. Thromb Res 1998; 92(suppl 1): S1-S6.
61. Forbes CD. Personal communication.
62. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
63. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from three clinical trials. Arch Intern Med 1998; 158: 1316-1320.
64. Stroke Prevention in Atrial Fibrillation Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with atrial fibrillation. Ann Intern Med 1998; 128: 639-647.
65. Stollberger C, Chnupa P, Kronik G et al. Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Int Med 1998; 128: 630-638.
66. Sudlow M, Thomson R, Thwaites B et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 325: 1167-1171.
67. Li-Saw-Hee FL, Lip GYH. Anticoagulation and atrial fibrillation (letter). ACC Curr Rev J 1998; May/June: 93-94.
68. Petersen P, Godfresen J. Embolic complications in paroxysmal atrial fibrillation. Stroke 1986; 17: 622-625.
69. Lip GYH. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk? Lancet 1997; 349: 1565-1566.
70. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a syudy in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29: 106-112.
71. Obarski TP, Salcedo EE, Castle LW, Stewart WJ. Spontaneous echo contrast in the left atrium during paroxysmal atrial fibrillation. Am Heart J 1990; 120: 988.
72. Lip GYH, Rumley A, Dunn FG, Lowe GD. Plasma fibrinogen and fibrin D-dimer levels in atrial fibrillation: effect of cardioversion to sinus rhythm. Int J Cardiol 1995; 51: 245-253.
73. Suttorp MJ, Kingma JH, Koomen EM et al. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 1993; 71: 710-713.
74. Clementy J, Dulhoste MN, Laiter C et al. Fleclainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol 1992; 70(suppl): 44A-49A.
75. Godtfredsen J. Atrial fibrillation, etiology, course, and prognosis: a follow-up of 1212 cases. In: Kulbertus HE, Olsson SB, Schlepper M, Eds. Atrial fibrillation. Molndal: AB Hassle 1982: 134-145.
76. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical cardioversion of atrial fibrillation. Am J Cardiol 1969; 23: 208.
77. Manning WJ, Silverman DI, Katz SE et al. Impaired left atrial mechanical function after cardioversion: relationship to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23: 1535-1540.
78. Grimm RA, Leung DY, Black IW et al. Left atrial appendage 'stunning' after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography. Am Heart J 1995; 130: 174-176.
79. Laupacis A, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation. Chest 1995: 108(suppl): 352S-359S.
80. Silverman DI, Manning WJ. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation 1998; 98: 479-486.
81. Klein AL, Grimm RA, Black IW et al. Cardioversion guided by transesophageal echocardiography: the ACUTE (Assessment of Cardioversion Using Transesophageal Echocardiography) Pilot Study, a randomized, controlled trial. Ann Intern Med 1997; 126: 200-209.
82. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
83. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649.
84. Lip GYH, Beevers DG. Interpretation of IST International Stroke Trial) and CAST (Chinese Acute Stroke Trial). Lancet 1997; 350: 443-444.
85. Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulalion (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-355.
86. Ezekowitz MD, Bridgers SL, James KE et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.